CoChat

Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL.

Maude, Shannon L., Teachey, David T., Rheingold, Susan R., Shaw, Pamela A, Aplenc, Richard, Barrett, David Maxwell, Barker, Christine S, Callahan, Colleen, Frey, Noelle V., Nazimuddin, Farzana, Lacey, Simon F., Zheng, Zhaohui, Levine, Bruce, Melenhorst, Jan Joseph, Motley, Laura, Porter, David L., June, Carl H., Grupp, Stephan A. · 2016 · Journal of Clinical Oncology
Cited by 149

The DOI matches its Crossref record.

Abstract

3011 Background: Targeted immunotherapy with chimeric antigen receptor (CAR)-modified T cells can produce potent anti-tumor responses. We previously reported complete remissions (CR) and prolonged persistence in children and adults with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL) treated with CD19-specific CART cells (CTL019). We now report on outcomes and longer follow-up of 59 children with r/r ALL. Methods: T cells collected from the patient were transduced with a lentiviral vector encoding a CAR composed of anti-CD19 scFv, CD3z, and 4-1BB domains, activated/expanded ex vivo with anti-CD3/CD28 beads, and then infused at a dose of 107 to 108cells/kg with a transduction efficiency of 2.3-45%. 54/59 patients received lymphodepleting chemotherapy the week prior to cell infusion. Results: Of 59 patients aged 20mo-24y with CD19+ ALL, 44 had detectable disease prior to CTL019 cell infusion, while 15 were MRD-. 39 were treated for relapse after prior stem cell transplant (SCT). 15 patients had CNS disease within a year of infusion. At assessment 1 month after infusion, 55/59 (93%) were in CR. MRD < 0.01% by flow cytometry was achieved in 52 patients. CTL019 cells were detected in the CSF and no CNS relapses have been seen. With median follow-up 12 mo (1-43 mo), 34 patients had ongoing CR, with only 6 receiving subsequent therapy (5 SCT, 1 donor lymphocyte infusion), RFS was 76% (95% CI, 65-89%) at 6 mo and 55% at 12 mo (95% CI, 42-73%), and OS was 79% (95% CI, 69-91%) at 12 mo. 20 patients subsequently relapsed, 13 with CD19- disease. CTL019 persistence was accompanied by B cell aplasia, which continued up to last assessment (1-39 mo) in 24/34 patients with ongoing CR. Cytokine release syndrome (CRS) was seen in 88% of patients. Severe CRS requiring hemodynamic or respiratory support occurred in 27%, was associated with high disease burden, and was reversed with the anti-IL6R agent tocilizumab. We could predict development of severe CRS through regression modeling using IFNγ, sgp130, and sIL1RA measured in the first 72h (sens 86%, spec 89%, AUC 0.93). Conclusions: Single-agent CTL019 immunotherapy can induce durable responses with control of CNS disease in patients with r/r ALL. Clinical trial information: NCT01626495.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.34.15_suppl.3011

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 149

Metadata

Authors
Maude, S. L., Teachey, D. T., Rheingold, S. R., Shaw, P. A., Aplenc, R., Barrett, D. M., Barker, C. S., Callahan, C., Frey, N. V., Nazimuddin, F., Lacey, S. F., Zheng, Z., Levine, B., Melenhorst, J. J., Motley, L., Porter, D. L., June, C. H., & Grupp, S. A.
Venue
Journal of Clinical Oncology
Published
2016-05-20
Volume
34
Issue
15_suppl
Pages
3011-3011
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2794874600
Cited by
149
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL. https://app.cochat.ai/papers/10.1200/jco.2016.34.15_suppl.3011
The paper
Maude, S. L., Teachey, D. T., Rheingold, S. R., Shaw, P. A., Aplenc, R., Barrett, D. M., Barker, C. S., Callahan, C., Frey, N. V., Nazimuddin, F., Lacey, S. F., Zheng, Z., Levine, B., Melenhorst, J. J., Motley, L., Porter, D. L., June, C. H., & Grupp, S. A. (2016). Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.34.15_suppl.3011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.